Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received May 14, 2008
- Revision received June 17, 2008
- Accepted July 1, 2008
- Published online September 1, 2008.
Copyright & Usage
Copyright© 2008 International Institute of Anticaner Research (Dr. John G. Delinassios), All rights reserved
Author Information
- JOANN P. PALMA,
- LUIS E. RODRIGUEZ,
- VELITCHKA D. BONTCHEVA-DIAZ,
- JENNIFER J. BOUSKA,
- GAIL BUKOFZER,
- MILAGROS COLON-LOPEZ,
- RAN GUAN,
- KENNETH JARVIS,
- ERIC F. JOHNSON,
- VERED KLINGHOFER,
- XUESONG LIU,
- AMANDA OLSON,
- MARY J. SALTARELLI,
- YAN SHI,
- JASON A. STAVROPOULOS,
- GUI-DONG ZHU,
- THOMAS D. PENNING,
- YAN LUO,
- VINCENT L. GIRANDA,
- SAUL H. ROSENBERG,
- DAVID J. FROST and
- CHERRIE K. DONAWHO
- Correspondence to: Cherrie K. Donawho, Abbott Laboratories, In Vivo Tumor Biology, Department R4N2, Bldg. AP3, Abbott Park, IL 60064, USA. Tel +1 8479376556, Fax: +1 8479384777, e-mail: cherrie.donawho{at}abbott.com
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- Complex Disease-, Gene-, and Drug-Drug Interactions: Impacts of Renal Function, CYP2D6 Phenotype, and OCT2 Activity on Veliparib Pharmacokinetics
- Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines
- Tripartite Motif-containing 33 (TRIM33) Protein Functions in the Poly(ADP-ribose) Polymerase (PARP)-dependent DNA Damage Response through Interaction with Amplified in Liver Cancer 1 (ALC1) Protein
- Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a Bona Fide PARP Inhibitor
- Contextual Synthetic Lethality of Cancer Cell Kill Based on the Tumor Microenvironment
- Bioenergetic Metabolites Regulate Base Excision Repair-Dependent Cell Death in Response to DNA Damage
- Potentiation of Temozolomide Cytotoxicity by Inhibition of DNA Polymerase {beta} Is Accentuated by BRCA2 Mutation
- ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors